Rheumatoid Arthritis Posts - Page 2 of 34 on Medivizor
Navigation Menu

Rheumatoid Arthritis Posts on Medivizor

Risk factors for fragility fractures in patients with rheumatoid arthritis.

Risk factors for fragility fractures in patients with rheumatoid arthritis.

Posted by on Oct 3, 2021 in Rheumatoid Arthritis | 0 comments

In a nutshell This study explored the risk factors for fragility fractures in patients with rheumatoid arthritis (RA). The authors concluded that aging, disease-related factors, and previous fracture history are important risk factors for fragility fractures in these patients. Some background RA is a chronic, systemic inflammatory disease that affects...

Read More

Can diet influence depression among patients with rheumatoid arthritis?

Can diet influence depression among patients with rheumatoid arthritis?

Posted by on Sep 26, 2021 in Rheumatoid Arthritis | 0 comments

In a nutshell This study investigated the relationships among depression and anxiety, diet, and disease activity or physical function in patients with rheumatoid arthritis (RA). The data showed that there was a relationship between depression and lower fish intake frequency in these patients.  Some background RA is a chronic inflammatory...

Read More

Comparing tofacitinib and baricitinib for patients with rheumatoid arthritis in a real-world setting

Comparing tofacitinib and baricitinib for patients with rheumatoid arthritis in a real-world setting

Posted by on Aug 22, 2021 in Rheumatoid Arthritis | 0 comments

In a nutshell This study compared the effectiveness and safety of tofacitinib (Xeljanz) and baricitinib (Olumiant) in patients with rheumatoid arthritis in a real-world setting. The data showed that tofacitinib and baricitinib had similar effectiveness and safety but clinical responses may depend on previous use of anti-rheumatic drugs. Some...

Read More

Can allergy and respiratory medications be used for rheumatoid arthritis?

Can allergy and respiratory medications be used for rheumatoid arthritis?

Posted by on Aug 15, 2021 in Rheumatoid Arthritis | 0 comments

In a nutshell This study investigated the effectiveness and safety of rupatadine (RUP; Rupafin) and montelukast (MON; Singulair) as additive therapies for patients with rheumatoid arthritis (RA). The authors concluded that RUP and MON provided clinical and functional improvements in these patients. Some background RA is a chronic autoimmune,...

Read More

How effective is bazedoxifene in preventing bone loss due to glucocorticoids in patients with rheumatoid arthritis?

How effective is bazedoxifene in preventing bone loss due to glucocorticoids in patients with rheumatoid arthritis?

Posted by on Aug 8, 2021 in Rheumatoid Arthritis | 0 comments

In a nutshell This study assessed the effectiveness of bazedoxifene (Duavee) in the prevention of bone loss in patients with rheumatoid arthritis (RA) while receiving low-dose glucocorticoid (GC) treatments. The data showed improved bone mineral density (BMD) and reduced bone turnover markers (BTMs) in these patients. Some background RA is a...

Read More

Can unacceptable pain be predicted in patients with early rheumatoid arthritis based on inflammation?

Can unacceptable pain be predicted in patients with early rheumatoid arthritis based on inflammation?

Posted by on Jul 31, 2021 in Rheumatoid Arthritis | 0 comments

In a nutshell This study investigated the duration, level, and predictors of unacceptable pain during the early stages of rheumatoid arthritis (RA), with and without low inflammation. The authors concluded that over a 5-year period, more than one-third of patients studied had unacceptable pain that was linked to lower swollen joints. Some background...

Read More

Is switching first-line targeted therapy for rheumatoid arthritis within 6 months of not reaching disease remission better than a traditional approach?

Is switching first-line targeted therapy for rheumatoid arthritis within 6 months of not reaching disease remission better than a traditional approach?

Posted by on Jul 25, 2021 in Rheumatoid Arthritis | 0 comments

In a nutshell This study investigated whether switching a first-line targeted therapy (TT) within 6 months of not attaining low disease activity (LDA) enhances the chance of patients with rheumatoid arthritis (RA) achieving their target at the 12-month visit. The data showed an increased chance of achieving a target of remission or LDA at the...

Read More

Is filgotinib with background methotrexate an option for patients with rheumatoid arthritis?

Is filgotinib with background methotrexate an option for patients with rheumatoid arthritis?

Posted by on Jul 21, 2021 in Rheumatoid Arthritis | 0 comments

In a nutshell This study compared the benefit of two doses of filgotinib (Jyseleca) with adalimumab (Humira) and placebo, in patients with rheumatoid arthritis (RA) treated with methotrexate (MTX; Otrexup). The data showed that filgotinib reduced RA signs, improved physical activity, prevented structural joint damage progression, and was...

Read More

Predicting the effectiveness of certolizumab pegol in rheumatoid arthritis by serum tumor necrosis factor alpha levels after 24 hours.

Predicting the effectiveness of certolizumab pegol in rheumatoid arthritis by serum tumor necrosis factor alpha levels after 24 hours.

Posted by on Jul 11, 2021 in Rheumatoid Arthritis | 0 comments

In a nutshell This study investigated the relationship between tumor necrosis factor-alpha (TNFα), interleukin (IL)-6, and serum certolizumab pegol (CZP; Cimzia) levels in patients with rheumatoid arthritis (RA) treated with CZP. The authors concluded that CZP was highly effective in patients with low serum TNFα levels at 24 hours after...

Read More

Do biological DMARDs affect fracture risk in patients with rheumatoid arthritis?

Do biological DMARDs affect fracture risk in patients with rheumatoid arthritis?

Posted by on Jun 30, 2021 in Rheumatoid Arthritis | 0 comments

In a nutshell This study analyzed the effect of using biological disease-modifying anti-rheumatic drugs (bDMARDs) on fracture risk in patients with rheumatoid arthritis (RA). The data suggest no evidence that the use of bDMARDs impacts fracture risk in these patients. Some background RA is a chronic, systemic (affects the whole body) inflammatory...

Read More

Can COVID-19 vaccines be used in patients with autoimmune rheumatic diseases?

Can COVID-19 vaccines be used in patients with autoimmune rheumatic diseases?

Posted by on Jun 13, 2021 in Rheumatoid Arthritis | 0 comments

In a nutshell This study described the guidelines from the Canadian Rheumatology Association (CRA) on the use of COVID-19 vaccines in patients with autoimmune rheumatic diseases (ARDs). The CRA recommended the use of Canada-approved COVID-19 vaccines for patients with ARDs. Some background ARDs include chronic, inflammatory conditions such as...

Read More